The long awaited arrival of Celera Genomics' Taiwan branch kicked off yesterday with the company, formerly billed as Celera Asia, being officially renamed Vita Genomics Inc (
Established in Taiwan with an eye for focusing on Asian specific genetic research, Vita Genomics plans to carry out gene sequencing in order to identify genes related to diseases common in Asia, such as liver and nasal cancer.
Ellson Chen (
The new company will be housed in the Taipei Biotechnology Park (台北生技園區) until construction is completed on its primary research center in the Tainan Science-based Industrial Park (台南科學園區). Once the Tainan location comes on line, the Taipei office will remain open as a branch office only. The company also opened a branch in Burlingame, California to handle bioinformatic research.
Although Vita's intended purpose and management team remain the same as previously reported, some of its strategies have changed.
Originally, Vita officials planned to raise NT$3.5 billion (US$100 million) to capitalize the venture, with major stakes going to Ho Tung Chemical, President Enterprises (
According to an anonymous source close to the situation, Celera is now part of the Vita deal with a US$5 million investment -- stock shares traded in return for unlimited access to Celera's extensive genetic database. (Originally, Celera was to invest up to 20 percent of the US$100 million needed to establish the company.)
Apparently, the management at Vita did not want Celera to have a seat on the company's board of directors "to prevent a potential future conflict" in the event that the two firms eventually become fierce competitors, the insider said.
Investors who have put up Vita's current financing include Ho Tung Chemical, China Development Industrial Bank (中華開發工銀), Cathay Life Insurance Co Ltd (國泰人壽), National Securities Corp (建弘證券) and the Executive Yuan's Development Fund (開發基金).
The arrival of Vita Genomics sent the stock of one of its prime investors, Ho Tung Chemical, up above 100 percent over the course of the year, doubling since Jan. 2 when it opened at NT$13.2.
In its last few sessions, the stock has gone on a wild ride. Last Friday, the stock price rose 6.15 percent in heavy trading, as 19.6 million shares of Ho Tung stock changed hands, far more than a normal trading day for the stock. Yesterday, the stock dropped 3 percent to NT$26.5, and analysts said the Friday session indicated that investors thought yesterday's announcement might be positive for the stock.
To highlight the importance officials place on the addition of Vita Genomics to Taiwan's biotechnology industry, the meeting held yesterday to introduce the firm attracted heavy hitters from Taiwan's biotech sector, including Academia Sinica (
MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it plans to double investment in data center-related technologies, including advanced packaging and high-speed interconnect technologies, to broaden the new business’ customer and service portfolios. The chip designer is redirecting its resources to data centers, mainly designing application-specific integrated circuits (ASIC) with artificial intelligence (AI) capabilities for cloud service providers. The data center business is forecast to lead growth in the next three years and become the company’s second-biggest revenue source, replacing chips used in smart devices, MediaTek president Joe Chen (陳冠州) told a media event in Taipei. “Three or four years
Until US President Donald Trump’s return a year ago, when the EU talked about cutting economic dependency on foreign powers — it was understood to mean China, but now Brussels has US tech in its sights. As Trump ramps up his threats — from strong-arming Europe on trade to pushing to seize Greenland — concern has grown that the unpredictable leader could, should he so wish, plunge the bloc into digital darkness. Since Trump’s Greenland climbdown, top officials have stepped up warnings that the EU is dangerously exposed to geopolitical shocks and must work toward strategic independence — in defense, energy and
Motorists ride past a mural along a street in Varanasi, India, yesterday.
For the second year in a row, a Brazilian movie has wowed international audiences and critics, securing multiple Oscar nominations and drawing fresh interest in the Latin American giant’s film industry. Experts say the success of The Secret Agent, which has won four Oscar nominations, a year after I Am Still Here won Brazil its first Oscar, is no fluke, with a bit of a push from the country’s political climate. “This is neither a coincidence nor a miracle. It is the result of a lot of work, consistent policies, and, of course, talent,” Ilda Santiago, director of the Rio International Film
RSS